贝伐珠单抗联合化疗治疗晚期结直肠癌的临床疗效

Efficacy of Bevacizumab Combination with Chemotherapy in the Treatment of Advanced Colorectal Cancer

目的：探讨晚期结直肠癌采用贝伐珠单抗联合化疗的临床疗效,为临床治疗提供参考。方法：按照随机数字表法将2010年2月～2013年2月我院收治的50例晚期结直肠癌患者分为两组,观察组采用贝伐珠单抗联合奥沙利铂,卡培他滨化疗,对照组单用奥沙利铂,卡培他滨进行化疗,比较两组的临床疗效、血清肿瘤标志物浓度变化及不良反应。结果：化疗4个周期后观察组有效率为56.00%高于对照组的24.00%,差异有统计学意义（P〈0.01）,观察组疾病控制率为84.00%高于对照组的60.00%,差异有统计学意义（P〈0.05）;观察组治疗后的CEA、CA242、CA19-9浓度均低于对照组,差异有统计学意义（P〈0.01）;化疗后两组不良反应主要有恶心、呕吐、食欲减低等胃肠道反应,乏力,肝功能损害,骨髓抑制,脱发,贫血以及中性粒细胞下降等,其中观察组乏力,肝功能损害发生率低于对照组,差异有统计学意义（P〈0.05）,其余不良反应两组差异无统计学意义（P〉0.05）。结论：结直肠癌采用贝伐珠单抗联合化疗治疗具有近期疗效好,安全性高等特点,临床有重要参考价值。

Objective： To explore the clinical efficacy of bevacizumab in combination with chemotherapy in the treatment of advanced colorectal cancer, and to provide reference for the clinical treatment. Methods： 50 cases of patients with advanced colorectal cancer in our hospital from February 2010 to February 2013 were divided into two groups according to the random number table method, the observation group were given bevacizumab combination with Oxaliplatin and Capecitabine, the control group was treated with Oxaliplatin,Capecitabine chemotherapy, the clinical effect, serum tumor marker concentration changes and adverse reactions of the two groups were compared. Results： After 4 cycles of chemotherapy, the effective rate of the observation group was 56.00%, higher than that of the control group （24.00%）, and the difference was statistically significant （P〈0.01）; the disease control rate of the observation group was 84.00%, higher than that of the control group （60.00%）, and the difference was statistically significant （P〈0.01）; After treatment, levels of CEA, CA242,CA19-9 in observation group was lower than those in control group, and the difference was statistically significant （P〈0.01）; Adverse reactions after chemotherapy included nausea and vomiting, loss of appetite, fatigue, gastrointestinal reaction, liver damage, bone marrow suppression, hair loss, anemia and neutropenia; the incidences of fatigue and liver function damage in observation group were lower than those in control group with statistical differences （P〈0.05）, other adversereactions in the two groups had no statistically significant difference （P〉0.05）. Conclusive： Bevacizumab combined with chemotherapy in treatment of advanced colorectal cancer has the characteristics of good recent curative effect and high security, and it has very important reference value in clinic.